Clinical Significance of Skin Toxicity due to EGFR-Targeted Therapies

被引：40

作者：

Giovannini, Monica ^{[1
]}

Gregorc, Vanesa ^{[1
]}

Belli, Carmen ^{[1
]}

Roca, Elisa ^{[1
]}

Lazzari, Chiara ^{[1
]}

Vigano, Maria Grazia ^{[1
]}

Serafico, Anna ^{[1
]}

Villa, Eugenio ^{[1
]}

机构：

[1] Ist Sci San Raffaele, Oncol Deptartment, 60 Olgettina St, I-20132 Milan, Italy

来源：

JOURNAL OF ONCOLOGY | 2009年 / 2009卷

关键词：

D O I：

10.1155/2009/849051

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Many small molecules and monoclonal antibodies blocking the activity of Epidermal Growth factor receptor (EGFR) have been developed and have shown clinical activity in patients with non-small cell lung cancer (NSCLC), pancreatic cancer, and colorectal cancer (CRC), and are in clinical development for a range of other solid tumors. The toxicity profile of such agents is characterized by a typical pattern of cutaneous reactions. In this paper we reviewed the current available data regarding the clinical significance of skin reaction due to EGFR targeted agents. We show that skin toxicity can be considered as predictive marker of response to such drugs and that it is not disease specific; however its potential prognostic value is still to be proven. Copyright (C) 2009 Monica Giovannini et al.

引用

页数：8

共 42 条

[1] Dermatologic side effects associated with the epidermal growth factor receptor inhibitors [J].

Agero, Anna Liza C. ;

Dusza, Stephen W. ;

Benvenuto-Andrade, Cristiane ;

Busam, Klaus J. ;

Myskowski, Patricia ;

Halpern, Allan C. .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2006, 55 (04) :657-670

[2] Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types [J].

Baselga, J ;

Rischin, D ;

Ranson, M ;

Calvert, H ;

Raymond, E ;

Kieback, DG ;

Kaye, SB ;

Gianni, L ;

Harris, A ;

Bjork, T ;

Averbuch, SD ;

Feyereislova, A ;

Swaisland, H ;

Rojo, F ;

Albanell, J .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (21) :4292-4302

[3]

BOKEMEYER C, 2007, P AN M AM SOC CLIN, V25, pS172

[4] The relationship of cetuximab-induced rash and survival in patients with head and neck cancer treated with radiotherapy and cetuximab [J].

Bonner, JA ;

Harari, PM ;

Giralt, J ;

Cohen, R ;

Baselga, J ;

Raben, D ;

Shin, DM ;

Ove, R ;

Jassem, J ;

Amellal, N ;

Azarnia, N ;

Ang, KK .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 63 (02) :S73-S73

[5]

Bruno R, 2003, P AN M AM SOC CLIN, V22, P205

[6] Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225 [J].

Busam, KJ ;

Capodieci, P ;

Motzer, R ;

Kiehn, T ;

Phelan, D ;

Halpern, AC .

BRITISH JOURNAL OF DERMATOLOGY, 2001, 144 (06) :1169-1176

[7]

CLARK GM, 2003, P AN M AM SOC CLIN, V22, P196

[8] Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck [J].

Cohen, EEW ;

Rosen, F ;

Stadler, WM ;

Recant, W ;

Stenson, K ;

Huo, DZ ;

Vokes, EE .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (10) :1980-1987

[9] Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer [J].

Cunningham, D ;

Humblet, Y ;

Siena, S ;

Khayat, D ;

Bleiberg, H ;

Santoro, A ;

Bets, D ;

Mueser, M ;

Harstrick, A ;

Verslype, C ;

Chau, I ;

Van Cutsem, E .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (04) :337-345

[10] Pharmacogenetics of ABCG2 and adverse reactions to gefitinib [J].

Cusatis, George ;

Gregorc, Vanesa ;

Li, Jing ;

Spreafico, Anna ;

Ingersoll, Roxann G. ;

Verweij, Jaap ;

Ludovini, Vienna ;

Villa, Eugenio ;

Hidalgo, Manuel ;

Sparreboom, Alex ;

Baker, Sharyn D. .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2006, 98 (23) :1739-1742

← 1 2 3 4 5 →